Patents Assigned to Ablynx N.V.
  • Immunoglobulin variable domains
    Patent number: 11220539
    Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).
    Type: Grant
    Filed: December 9, 2020
    Date of Patent: January 11, 2022
    Assignee: Ablynx N.V.
    Inventors: Marie-Ange Buyse, Carlo Boutton
  • TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
    Publication number: 20210403536
    Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).
    Type: Application
    Filed: August 23, 2021
    Publication date: December 30, 2021
    Applicant: Ablynx N.V.
    Inventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Néotère Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
  • Polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP
    Patent number: 11208476
    Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.
    Type: Grant
    Filed: March 22, 2021
    Date of Patent: December 28, 2021
    Assignees: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernd Weigle, Klaus Erb
  • T CELL RECRUITING POLYPEPTIDES BASED ON TCR ALPHA/BETA REACTIVITY
    Publication number: 20210395398
    Abstract: T cell recruiting polypeptides are provided that bind the constant domain of TCR on a T cell. The polypeptides can be used in methods for treatment of cancers.
    Type: Application
    Filed: December 21, 2020
    Publication date: December 23, 2021
    Applicant: Ablynx N.V.
    Inventors: Annelies Roobrouck, Diane Van Hoorick, João Vieira
  • TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
    Publication number: 20210388061
    Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).
    Type: Application
    Filed: August 23, 2021
    Publication date: December 16, 2021
    Applicant: Ablynx N.V.
    Inventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Néotère Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
  • TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
    Publication number: 20210388062
    Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).
    Type: Application
    Filed: August 23, 2021
    Publication date: December 16, 2021
    Applicant: Ablynx N.V.
    Inventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Néotère Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
  • Serum albumin binding proteins containing immunoglobulin single variable domains
    Patent number: 11192938
    Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference and/or give rise to an (aspecific) signal in such an assay (such as in an ADA immunoassay; methods for modifying and/or improving ISV's to as to remove or reduce their tendency to give rise to such protein interference or such a signal; modifications that can be introduced into an ISV that remove or reduce its tendency to give rise to such protein interference or such a signal; ISV's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er)/reduced tendency to give rise to such protein interference or such a signal; modified and/or improved ISV's that have no or a low(er)/reduced tendency to give rise to such protein interference or such a signal.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: December 7, 2021
    Assignee: Ablynx N.V.
    Inventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Neotere Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
  • Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
    Patent number: 11192937
    Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: —assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: December 7, 2021
    Assignee: Ablynx N.V.
    Inventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Neotere Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
  • CHROMATOGRAPHY-FREE ANTIBODY PURIFICATION METHOD
    Publication number: 20210371457
    Abstract: The present invention relates method for purifying antibodies, said method comprising a limited number of steps while still allowing obtaining high yields of purified antibodies with an appropriate degree of purity. Briefly, this method comprises only filtration and precipitation steps, omitting the need for chromatography steps.
    Type: Application
    Filed: October 8, 2019
    Publication date: December 2, 2021
    Applicant: Ablynx N.V.
    Inventors: Peter Casteels, Willem Van De Velde, Anthony Van De Putte, Sindi De Vrieze
  • T CELL RECRUITING POLYPEPTIDES BASED ON CD3 REACTIVITY
    Publication number: 20210363251
    Abstract: T cell recruiting polypeptides are provided that bind CD3 on a T cell. The polypeptides can be used in methods for treatment of cancers.
    Type: Application
    Filed: May 3, 2021
    Publication date: November 25, 2021
    Applicant: Ablynx N.V.
    Inventors: Annelies Roobrouck, Diane Van Hoorick, João Vieira
  • METHODS AND COMPOSITIONS FOR THE PREPARATION OF AEROSOLS
    Publication number: 20210346287
    Abstract: The present invention relates to methods for the preparation of an aerosol. More specifically the present invention provides methods for the preparation of an aerosol of immunoglobulin single variable domains wherein the amount of aggregate formation is significantly reduced. The invention further provides aerosols prepared by the methods of the invention, as well as compositions for use in the methods of the invention. The invention further relates to methods for the preparations of such compositions, to containers, kits and aerosol delivery systems comprising such compositions and to uses of the same.
    Type: Application
    Filed: April 19, 2021
    Publication date: November 11, 2021
    Applicant: Ablynx N.V.
    Inventors: Erik Depla, Mauro Sergi, Peter Casteels
  • METHODS FOR DETECTING AND/OR MEASURING ANTI-DRUG ANTIBODIES, IN PARTICULAR TREATMENT-EMERGENT ANTI-DRUG ANTIBODIES
    Publication number: 20210341490
    Abstract: Described herein are methods, assays and techniques for detecting and/or measuring anti-drug antibodies that bind to a protein, polypeptide or other compound or molecule that comprises at least one immunoglobulin variable domain with an exposed C-terminal region.
    Type: Application
    Filed: April 13, 2021
    Publication date: November 4, 2021
    Applicant: Ablynx N.V.
    Inventors: Veerle Snoeck, Marie-Ange Buyse, Judith Baumeister
  • KV1.3 binding immunoglobulins
    Patent number: 11149086
    Abstract: The present invention relates to immunoglobulins that specifically bind Kv1.3 and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Kv1.3.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: October 19, 2021
    Assignee: Ablynx N.V.
    Inventors: Diane Van Hoorick, Erik Depla, Frank Kamiel Delphina Verdonck, Veerle Delanote, Daniel Janssen, Francis Descamps, Mark Edward Labadia, Ann Mikhail, Alisa K. Waterman
  • Method for treating rheumatoid arthritis by administering IL-6 receptor antibodies
    Patent number: 11149089
    Abstract: Polypeptides are provided directed against IL-6R at specific dose ranges and dosing schedules that result in a prolonged effect on IL-6 mediated signaling. In particular, the invention provides pharmacologically active agents, compositions, methods and/or dosing schedules that have certain advantages compared to the agents, compositions, methods and/or dosing schedules that are currently used and/or known in the art, including the ability to dose less frequently or to administer lower doses to obtain equivalent effects in inhibiting IL-6 mediated signaling.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: October 19, 2021
    Assignee: Ablynx N.V.
    Inventors: Josefin-Beate Holz, Stefaan Rossenu, Steven De Bruyn, Maria-Laura Sargentini-Maier, Özkan Yalkinoglu
  • Serum albumin-binding immunoglobulin variable domains
    Patent number: 11142569
    Abstract: The present invention relates to amino acid sequences binding to serum albumin. In particular, the present invention relates to improved immunoglobulin single variable domains (also referred to herein as “ISV's” or “ISVD's”), and more in particular improved heavy-chain immunoglobulin single variable domains, binding to serum albumin, as well as to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise such improved serum albumin binders.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: October 12, 2021
    Assignee: Ablynx N.V.
    Inventor: Marie-Ange Buyse
  • IMMUNOGLOBULIN VARIABLE DOMAINS
    Publication number: 20210269514
    Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).
    Type: Application
    Filed: March 29, 2021
    Publication date: September 2, 2021
    Applicant: Ablynx N.V.
    Inventors: Marie-Ange Buyse, Carlo Boutton
  • IMMUNOGLOBULIN VARIABLE DOMAINS
    Publication number: 20210269515
    Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which a is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).
    Type: Application
    Filed: March 29, 2021
    Publication date: September 2, 2021
    Applicant: Ablynx N.V.
    Inventors: Marie-Ange Buyse, Carlo Boutton
  • IMMUNOGLOBULIN VARIABLE DOMAINS
    Publication number: 20210261653
    Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).
    Type: Application
    Filed: March 29, 2021
    Publication date: August 26, 2021
    Applicant: Ablynx N.V.
    Inventors: Marie-Ange Buyse, Carlo Boutton
  • NOVEL ANTIGEN BINDING DIMER-COMPLEXES, METHODS OF MAKING/AVOIDING AND USES THEREOF
    Publication number: 20210246192
    Abstract: In a broad aspect the present invention generally relates to novel dimer-complexes (herein called “non-fused-dimers” or NFDs) comprising single variable domains, methods of making these complexes and uses thereof. These non-covalently bound dimer-complexes consist of two identical monomers that each comprises of one or more single variable domains (homodimers) or of two different monomers that each comprises on or more single variable domains (heterodimers). The subject NFDs have typically altered e.g. improved binding characteristics over their monomeric counterpart. The NFDs of the invention may further be engineered through linkage by a flexible peptide or cysteines in order to improve the stability. This invention also describes conditions under which such NFDs are formed and conditions under which the formation of such dimers can be avoided.
    Type: Application
    Filed: January 5, 2021
    Publication date: August 12, 2021
    Applicant: Ablynx N.V.
    Inventors: Ann Brigé, Christine Labeur, Marc Jozef Lauwereys
  • IMPROVED IMMUNOGENICITY ASSAYS
    Publication number: 20210239709
    Abstract: The present invention relates to improved immunogenicity assays and methods for performing the same. In particular, the present invention relates to improved immunogenicity assays that are capable of distinguishing neutralizing anti-drug antibodies from non-neutralizing anti-drug antibodies. More in particular, the present invention relates to improved immunogenicity assays that allow (amounts and/or concentrations of) neutralizing anti-drug antibodies to be detected and/or measured in a sample even in the presence of non-neutralizing anti-drug antibodies.
    Type: Application
    Filed: March 29, 2018
    Publication date: August 5, 2021
    Applicant: Ablynx N.V.
    Inventors: Annelies Coddens, Veerle Snoeck, Marie-Ange Buyse, Carlo Boutton